2025Nature Communications16 (1) : 1995
Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
Ssebyatika G, Dinkelborg K, Ströh L, Hinte F, Corneillie L, Hueffner L, Guzman E, Nankya P, Plückebaum N, Fehlau L, Garn J, Meyer N, Prallet S, Mehnert A, Kraft A, Verhoye L, Jacobsen C, Steinmann E, Wedemeyer H, Viejo-Borbolla A, Dao Thi V, Pietschmann T, Lütgehetmann M, Meuleman P, Dandri M, Krey T, Behrendt P
2024Nature Communications15 (1) : 4855
Genetic determinants of host- and virus-derived insertions for hepatitis E virus replication
Wißing M, Meister T, Nocke M, Gömer A, Masovic M, Knegendorf L, Brüggemann Y, Bader V, Siddharta A, Bock C, Ploss A, Kenney S, Winklhofer K, Behrendt P, Wedemeyer H, Steinmann E, Todt D
2024One Health (amsterdam, Netherlands)18 : 100674
Immunisation of pigs with recombinant HEV vaccines does not protect from infection with HEV genotype 3
Dähnert L, Aliabadi E, Fast C, Hrabal I, Schröder C, Behrendt P, Protzer U, Groschup M, Eiden M
2024Jhep Reports : Innovation in Hepatology6 (3) : 100989
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment
Gömer A, Dinkelborg K, Klöhn M, Jagst M, Wißing M, Frericks N, Nörenberg P, Behrendt P, Cornberg M, Wedemeyer H, Steinmann E, Maasoumy B, Todt D
2023Emerging Microbes & Infections12 (2) : 2251598
Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
Stahl Y, Kabar I, Heinzow H, Maasoumy B, Bremer B, Wedemeyer H, Schmidt H, Pietschmann T, Schlevogt B, Behrendt P
2023Hepatology (baltimore, Md.)78 (6) : 1882-1895
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients
Gömer A, Klöhn M, Jagst M, Nocke M, Pischke S, Horvatits T, Schulze Zur Wiesch J, Müller T, Hardtke S, Cornberg M, Wedemeyer H, Behrendt P, Steinmann E, Todt D
2023Antiviral Research217 : 105690
Janus kinase-inhibition modulates hepatitis E virus infection
Kinast V, Andreica I, Ahrenstorf G, Gömer A, Elsner C, Schlienkamp S, Schrader J, Klöhn M, Ulrich R, Broering R, Vondran F, Todt D, Behrendt P, Dittmer U, Hamprecht A, Witte T, Baraliakos X, Steinmann E
2023Hepatology (baltimore, Md.)77 (6) : 2104-2117
EGF receptor modulates HEV entry in human hepatocytes
Schrader J, Burkard T, Brüggemann Y, Gömer A, Meister T, Fu R, Mehnert A, Dao Thi V, Behrendt P, Durantel D, Broering R, Vondran F, Todt D, Kinast V, Steinmann E
2023Hepatology (baltimore, Md.)77 (5) : 1475-1477
Urine: a place where HEV cannot hide!
Behrendt P, Gouttenoire J
2023Alimentary Pharmacology & Therapeutics57 (1) : 136-145
Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis
Tergast T, Schulte B, Griemsmann M, Kahlhöfer J, Dörge P, Hinrichs J, Kraft A, Schmidt J, Behrendt P, Wedemeyer H, Cornberg M, Maasoumy B